List of Excipients in API erlotinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing erlotinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | CELLULOSE, MICROCRYSTALLINE | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | FD&C YELLOW NO. 6 | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | HYDROXYPROPYL CELLULOSE | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | HYPROMELLOSES | |
| Physicians Total Care Inc | TARCEVA | erlotinib hydrochloride | 54868-5290 | LACTOSE MONOHYDRATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing erlotinib
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 | CELLULOSE, MICROCRYSTALLINE |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 | HYPROMELLOSE 2910 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 | LACTOSE MONOHYDRATE |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 | MAGNESIUM STEARATE |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 | POLYDEXTROSE |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for erlotinib
Excipient focus: CELLULOSE, MICROCRYSTALLINE
erlotinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| >Company | >Ingredient | >NDC |
Excipient focus: CROSPOVIDONE
erlotinib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
erlotinib drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | erlotinib hydrochloride | 54868-5290 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
erlotinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Alembic Pharmaceuticals Limited | erlotinib hydrochloride | 46708-565 |
| Physicians Total Care Inc | erlotinib hydrochloride | 54868-5290 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
erlotinib drug variants containing HYPROMELLOSE
erlotinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2208
erlotinib drug variants containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing HYPROMELLOSE 2208
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
erlotinib drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing HYPROMELLOSE 2910
Excipient focus: HYPROMELLOSES
erlotinib drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Physicians Total Care Inc | erlotinib hydrochloride | 54868-5290 |
| MSN LABORATORIES PRIVATE LIMITED | erlotinib hydrochloride | 69539-090 |
| Novadoz Pharmaceuticals LLC | erlotinib hydrochloride | 72205-080 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
erlotinib drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
erlotinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 101
erlotinib drug variants containing MICROCRYSTALLINE CELLULOSE 101
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing MICROCRYSTALLINE CELLULOSE 101
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 102
erlotinib drug variants containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing MICROCRYSTALLINE CELLULOSE 102
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 112
erlotinib drug variants containing MICROCRYSTALLINE CELLULOSE 112
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing MICROCRYSTALLINE CELLULOSE 112
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYDEXTROSE
erlotinib drug variants containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing POLYDEXTROSE
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
erlotinib drug variants containing POLYETHYLENE GLYCOL
erlotinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
erlotinib drug variants containing POLYETHYLENE GLYCOL 400
erlotinib drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
erlotinib drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 8000
erlotinib drug variants containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
erlotinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| MSN LABORATORIES PRIVATE LIMITED | erlotinib hydrochloride | 69539-090 |
| Novadoz Pharmaceuticals LLC | erlotinib hydrochloride | 72205-080 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
erlotinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| Mylan Pharmaceuticals Inc | erlotinib hydrochloride | 0378-7131 |
| Mylan Institutional Inc | erlotinib hydrochloride | 42292-051 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM LAURYL SULFATE
erlotinib drug variants containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing SODIUM LAURYL SULFATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
erlotinib drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STEARYL FUMARATE
erlotinib drug variants containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Breckenridge Pharmaceutical Inc | erlotinib hydrochloride | 51991-890 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing SODIUM STEARYL FUMARATE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
erlotinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| Zydus Lifesciences Limited | erlotinib | 70771-1521 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
erlotinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
erlotinib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7662 |
| Teva Pharmaceuticals USA Inc | erlotinib | 0093-7663 |
| >Company | >Ingredient | >NDC |
erlotinib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Camber Pharmaceuticals Inc | erlotinib | 31722-263 |
| Aurobindo Pharma Limited | erlotinib | 59651-530 |
| Areva Pharmaceuticals | erlotinib | 59923-727 |
| Sun Pharmaceutical Industries Inc | erlotinib | 63304-095 |
| Zydus Pharmaceuticals USA Inc | erlotinib | 68382-913 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
